Compare Autodesk Inc (ADSK) vs AstraZeneca plc (AZN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Autodesk Inc vs AstraZeneca plc — how do they compare? Autodesk Inc trades at $247.92 (market cap $53.12B), while AstraZeneca plc trades at $157.92 (market cap $248.14B). The key difference: AstraZeneca plc is far larger — about 4.7× Autodesk Inc's market cap, and AstraZeneca plc pays a 2.01% dividend while Autodesk Inc pays none. Which is the better fit depends on your goals.
| ADSK | AZN | |
|---|---|---|
Market Cap | $53.12B | $248.14B |
Sector | Technology | Health |
52-Week High | $326.79 | $209.48 |
52-Week Low | $187.72 | $147.06 |
Enterprise Value | $52.92B | $275.41B |
Dividend Yield | — | 2.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Autodesk (ADSK) trades at $256.07, up 2.81% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with revenue growth from $4.4B in 2022 to $6.1B in 2025, net income margin expanding to 19.49%, and consistent earnings beats. Recent news highlights AI investments and upcoming Q2 2027 earnings call on August 27, 2026.
Outlook remains positive with 74.5% analyst buy ratings and $302.23 consensus target offering 18% upside. Key risks include elevated valuation multiples (P/E 36.73) and competitive pressures in design software. The stock's technical strength and fundamental growth trajectory support continued investor interest despite overbought RSI signals.
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Autodesk Inc
Founded in 1982, Autodesk is an application software company that serves industries in architecture, engineering, and construction.
Read more on ADSK →About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →
